The 2024 European clinical practice guidelines introduce a pivotal terminology shift, replacing NAFLD (non-alcoholic fatty liver disease) with MASLD (metabolic dysfunction-associated steatotic liver ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

Eli Lilly (LLY) raised its full-year forecast after beating second quarter expectations, but shares slipped as its ...

A DAILY weight loss pill that works like Ozempic can help users shed an average of almost two stone,  a study reveals. People ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.